Showing results (11-20 of 25) with videos related to
Sort By:
Pageof 3
Frontiers in Oncology|September 27, 2021
A Phase I Trial of Dasatinib and Osimertinib in TKI Naïve Patients With Advanced EGFR-Mutant Non-Small-Cell Lung CancerChul Kim, Stephen V Liu, Jennifer Crawford, et al.Journal of Medical Economics|February 12, 2021
Real-world impact of brain metastases on healthcare utilization and costs in patients with non-small cell lung cancer treated with EGFR-TKIs in the USAmanda M Kong, Melissa Pavilack, Hairong Huo, et al.The Oncologist|March 8, 2019
Clinical Activity of Nivolumab for Human Papilloma Virus-Related Juvenile-Onset Recurrent Respiratory PapillomatosisBen C Creelan, M Usman Ahmad, Frank J Kaszuba, et al.Cancer Chemotherapy and Pharmacology|March 30, 2017
A phase Ib/II study of cabozantinib (XL184) with or without erlotinib in patients with non-small cell lung cancerHeather A Wakelee, Scott Gettinger, Jeffrey Engelman, et al.Cancer Chemotherapy and Pharmacology|September 21, 2019
A phase I study of HER1, HER2 dual kinase inhibitor lapatinib plus the proteasome inhibitor bortezomib in patients with advanced malignanciesFilipa Lynce, Hongkun Wang, Emanuel F Petricoin, et al.Cancer|January 26, 2021
Treatment with pembrolizumab in programmed death ligand 1-positive recurrent glioblastoma: Results from the multicohort phase 1 KEYNOTE-028 trialDavid A Reardon, Tae Min Kim, Jean-Sebastien Frenel, et al.Frontiers in Oncology|September 27, 2018
Long-Term Outcomes Following Conventionally Fractionated Stereotactic Boost for High-Grade Gliomas in Close Proximity to Critical Organs at RiskMichael C Repka, Siyuan Lei, Lloyd Campbell, et al.Journal of Neuropathology and Experimental Neurology|May 3, 2018
Targetable Gene Fusions Associate With the IDH Wild-Type Astrocytic Lineage in Adult GliomasSherise D Ferguson, Shouhao Zhou, Jason T Huse, et al.The Lancet. Oncology|February 4, 2018
Pembrolizumab in patients with thymic carcinoma: a single-arm, single-centre, phase 2 studyGiuseppe Giaccone, Chul Kim, Jillian Thompson, et al.British Journal of Cancer|March 13, 2018
A phase 1 dose-escalation study of veliparib with bimonthly FOLFIRI in patients with advanced solid tumoursJordan Berlin, Ramesh K Ramanathan, John H Strickler, et al.Pageof 3